INSIDE INFORMATION
RECOMBINANT COVID-19 VACCINE (ADENOVIRUS TYPE 5 VECTOR)
FOR INHALATION
INCLUDED FOR EMERGENCY USE AS BOOSTER VACCINE IN CHINA

This announcement is made by CanSino Biologics Inc. (the “Company”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

The Company is pleased to announce that, as proposed by the National Health Commission of the People`s Republic of China (the “PRC”) and approved by the National Medical Products Administration of the PRC (the “NMPA”) upon demonstration, the Company’s Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) for Inhalation (the “Ad5-nCoV for Inhalation”) has been included for emergency use as a booster vaccine in the PRC. Further purchases by relevant national authorities, if any, will have certain positive effects on the results of the Company.

Ad5-nCoV for Inhalation is a genetic engineered inhaled vaccine to prevent COVID-19 disease, which can not only stimulate humoral and cellular immunity, but also induce mucosal immunity to achieve triple comprehensive protection efficiently without intramuscular injection. Ad5-nCoV for Inhalation has unique advantages of safety, effectiveness, painlessness, convenience and availability. As announced by the Company on March 23, 2021, the clinical trial application for the Ad5-nCoV for Inhalation has been approved by the NMPA.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, September 4, 2022